In early phase I trials, PD1-PD-L1 axis blockade alone has yielded promising results in a variety of cancer types; in melanoma, the anti-PD1 antibody nivolumab has shown sufficient clinical responses which are often durable, with some patients remaining free from disease progression for many years [87]. This evidence concerns the gene PDCD1 and melanoma.